Country dialysis patient faces choice of moving to Adelaide or stopping treatment
These are the options Chris Thomas, a 68-year-old Crystal Brooke resident in the mid-north of South Australia, faces.
The retired farmer has been receiving treatment in the Lyell McEwin Hospital in Adelaide since May after he had two major cardiac arrests while undergoing rehabilitation following the amputation of a leg.
This is in addition to him needing regular dialysis, treatment he had been receiving in Port Pirie for the past four years.
Given his complex medical conditions, Mr Thomas was told he was not medically fit to be discharged from hospital or for transfer to Port Pirie.
So now he and his family are facing the tough choice: move to Adelaide or effectively give up medical support.
His daughter Alex Thomas was disappointed more effort hadn't been made to find alternative options for her father given he had lived in the country his whole life and didn't want to move to the city.
"And that when you're vulnerable and when you reach your 11th hour of life that you're going to be able to stay within your home no matter what your postcode is."
Ms Thomas has made an impassioned plea to SA Health to investigate options that would allow her father to return home and keep receiving treatment.
"I want them to honour his desire to go home," she said.
"I want them to cease discriminating against him because he lives in a regional area."
SA Health Minister Chris Picton said his office had reached out to Mr Thomas's family, and there would be a senior medical review of his case to "see what options could be available".
"We provide dialysis services right across the state, but there are obviously some levels of medical conditions that people have where they do need to be in a tertiary hospital setting," Mr Picton said.
"Ultimately, in a state like South Australia, we can't provide the quaternary level of hospital care and the sub-speciality level of hospital care in each locality of everywhere across regional South Australia.
Satellite dialysis units and home dialysis services are available across a number of the state's metropolitan and regional health services, but are designed to care for less complex and lower-risk patients.
In a statement, SA Health extended its "sincerest sympathies to Mr Thomas and his family, who are navigating an incredibly difficult time".
"Due to Mr Thomas's ongoing, high-risk medical issues, he is not medically fit for discharge from Lyell McEwin Hospital, or for transfer to Port Pirie," the statement said.
"The health and wellbeing of our patients is always our priority.
Ms Thomas however said that it was important to her dad, who had worked as a farmer and pastoralist as well as at Roxby Downs, that he spend the rest of his days living and receiving treatment in the bush.
"It's his choice, no-one is more acutely aware of his mortality than he is," Ms Thomas said.
"If he moves to Adelaide he is going to be grossly isolated from everything he has ever known.
SA Health staff said at no stage had Mr Thomas or his family been advised that he should withdraw from medical care.
The Port Pirie Satellite Dialysis Unit offers expert care in renal dialysis; like other satellite dialysis units, Port Pirie offers care for stable, lower-complexity patients.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
an hour ago
- News.com.au
Dr Boreham's Crucible: ASX newbie Tetratherix plays it slow and steady
By taking the 'less is more' approach to funding, the backers of the first ASX life sciences initial public offer (IPO) in seven months have been rewarded with a robust share price over the first few trading days. The developer of the world's first 'bio-stealth fluid matrix' wound management house, Tetratherix (ASX:TTX) listed on Monday after reducing the size of its raising from $35 million to $25 million. 'This IPO is not an endpoint or an exit strategy, rather a foundation upon which we will accelerate product development, expand our global clinical footprint and scale manufacturing and commercial operations,' CEO Will Knox declared. The company's Tetramatrix platform has nothing to do with stealth fighters or furtive FBI agents, but is the basis of novel tools for applications including tissue healing, bone regeneration and surgical spacing. 'Bio-stealth refers to the ability to quietly enter the body through minimally invasive means,' Knox says. 'It tricks the body, so it doesn't know it has been in there and done the things it needs to do before being reabsorbed. 'That's important because the product doesn't elicit any inflammatory or foreign body response.' Knox dubs the platform as 'medical Lego', in that the products are built from the same polymer structure. 'That means you can use the same underlying biological performance and safety data in all regulatory applications,' he says. 'Our path to market is a lot faster and simpler because the data is interchangeable across the different applications.' 'Intelligent chemistry' The technology combines four liquid monomers in ready-to-use syringes. The 'intelligent chemistry' means it sets to a chewing-gum consistency at body temperature, causing minimal damage to other tissue. The material avoids the fibrotic response associated with healing. 'The ethos is to have something everyone can use, without changing clinical workflows,' says Dr Ali Fathi, the company's co- founder. 'Even a first-year school student can use it.' The material can be easily moulded to suit the application and is not rejected by the body. Eventually, the material breaks down into water and carbon dioxide. These qualities make it suitable for day surgeries, which are increasingly common. Tetratherix currently does not have an approved product. Pending expected US Food and Drug Administration approval, the company hopes to launch products for dental applications, bone regeneration and orthopaedic uses next year. This thesis was more than theory Academic theses tend to be derided as esoteric or theoretical - or both. That's not the case with University of Sydney researcher and chemical engineer Dr Fathi, whose thesis spawned the Tetra-tech. The topic? 'Injectable Hydrogels with Tunable Physico-chemical Characteristics and Cell-interactive Behaviour for Musculo-skeletal Tissue Regeneration'. Dr Fathi and Terence Abrams formed the company, then known as Trimph Holdings, in 2025. In 2018, a dental clinical study established the technology's street cred. The company adopted its current moniker in 2020 and carried out its first private fund-raising (series A round) for $2.5 million of preference shares. This was followed by two convertible note raisings, totalling $8.45 million. The company then converted to an unlisted public company structure. Knox has extensive experience on commercializing regenerative therapies including at Cochlear. The board includes John Kelly, co-founder of the ASX-listed Atomo Diagnostics. With an initial focus on dermal repair and orthopaedic bone regeneration, Tetratherix expanded into surgical spacing and tissue healing (preventing scars forming in surgery) The company also plans to commercialise a 'spacer' to protect surrounding tissue (such as the rectum) during prostate cancer radiation therapy. Tegenix … First off the commercialisation rank is the company's dental bone regeneration tool, Tegenix. Clinicians mix the material for a bone graft. The putty is then pressed into the bone defect, providing flexibility. 'It also means general dentists can carry out some of these more complex procedures,' Knox says. Tetratherix has carried out two clinical trials that show Tegenix supports natural bone healing. The company expects to bring Tegenix to market by July 2026, following expected FDA clearance. Identical in chemistry to Tegenix, fast follower Tegeneous is intended for orthopaedic uses, enabling minimally invasive treatment of trauma and spinal injuries. Tutelix … Under a joint venture with the local Koda Health, Tetratherix is developing Tutelix for prostate spacing. The material is injected through a long needle between the prostate and the rectum, which protects the latter from radiation during prostate procedures. 'We make cancer radiation therapy safer and simpler. It provides clinicians with optionality in that they can inject it at the pace they want,' Knox says. 'It's visible under a scan and ultrasound, enabling precision.' The joint venture has ethics approval for a human trial, expected to start within weeks. On the ophthalmic front, the Tetratherix 'eyes' a product called Optelex, to maintain the volume and shape of peepers during surgery. … and Tetraderm Tetraderm prevents scar formation after procedures such as caesarean sections and breast augmentation and reductions. The product forms a gel between layers of the dermal tissue, reducing 'dead space' and providing cushioning to prevent scar formation. Carried out on the Gold Coast, a trial has passed the first safety and efficacy hurdles. The company expects a pre-submission meeting with the FDA by the end of 2026. In the fast lane Knox says Tetratherix is taking the relatively easy FDA 510(k) path to market. 'We are not a drug, so don't need phase I to III style programs,' he says. 'The average time for an FDA response is 124 calendar days, rather than months or years.' The company's regulatory team sifted through 300 510(k) applications and discovered a 95% success rate. 'It is a much lower risk profile from a market access perspective.' Take your partners Management describes a dual revenue model, by which the technology is licenced to partners in a specific field. This approach means the company does not have to set up a large marketing team: 'an expensive and arduous process'. The partners have the right to self-fund expanded indications, with Tetratherix providing the material. For Tegenix, the company has an agreement with Henry Schein, the world's biggest dental supplier. Tetratherix has teamed up New York's Bio-Optix Inc to develop and commercialise a novel ophthalmic visco-elastic device (for cataract surgery). Knox describes the partnerships as distinct and long term. 'We try to avoid the difficult two-to-three-year distribution arrangement,' he says. 'Over many years I have found that doesn't provide enough long-term stability. 'Our partnerships are more a co-development agreement over 15 to 20 years.' Made in Australia US tariffs aside – and such imposts shouldn't overly affect the company – Tetratherix is intent at keeping its manufacturing and development on local shores. 'We are setting ourselves up to be an Australian leader in advanced material manufacturing in the biological and medical device space,' Knox says. The polymers are made at the company's facility at Alexandria, near Sydney Airport. About $10 million IPO proceeds are earmarked for a new plant around the corner, with 10 times the capacity. Knox says the products are made from widely available raw materials, using 'catalogue' equipment. 'The smarts are how you combine and cook those ingredients and how the parts of the process are put in place.' Finances and performance The IPO consisted of an institutional round and limited retail offering, raising $25 million at $2.88 a pop. The shares jumped 15% after listing on Monday and now are more than 50% to the good – a lusty showing indeed. Knox says the company could have raised the $35 million but wanted to avoid 'fast money' subscribers unlikely to stick around. The company now has cash on hand of circa $30 million. This funding provides a runway to mid-2027. It factors in two FDA approvals, one further submission and 'multiple clinical trial readouts'. Knox says the company has spent about $15 million in research and development over the last decade, with little extra spending required. Currently, US reimbursement depends on the product. With bone regeneration, the patient pays out of pocket in what's a low-cost, high-volume game. But prostate spacing has a well-defined US reimbursement model. Tetratherix expects milestone licensing payments, as well as on-going annuity-style revenue from licencing and manufacturing margins. The register includes Rod Drury, who founded small to middle sized enterprise (SME) 'software as a service' (SaaS) accounting pioneer Xero. Mr Drury says he was attracted to Tetratherix because the company applies 'SaaS platform thinking' to smart medical devices. Dr Boreham's diagnosis Knox says the IPO coincides with the company maturing from research and development stage to a commercially focused entity. The company cites a combined addressable market for bone regeneration, tissue spacing and tissue healing at US$6.8 billion and forecast to grow to US$9.5 billion by 2023. 'We have five very distinct products across three franchises, built on a platform opportunity,' Knox says. Still, wound-care newbies need to prove they have the superior – or cheaper – mousetrap. That often doesn't work. This week, the struggling ASX-listed Next Science said it would sell most of its assets to an Italian acquiror for US$50 million ($75.9 million). Knox says, typically, the company won't compete with ASX peers such as Aroa Biosurgery, Avita, Orthocell and Polynovo. 'Instead, we try to disrupt markets, such as in bone regeneration in dental and orthopaedic procedures. Tetratherix management is most excited about Tutelix and Tetraderm, given their potential to displace incumbent products from sector giants like Teleflex and Boston Scientific. First thing's first, though: Tetratherix needs to win the two initial FDA approvals and start to accrue that annuity revenue. But Knox says Wound mana will take it slowly, wooing the top opinion-leading clinicians before tackling the others. 'There is a very deliberate and strategic way of launching these products,' he says. 'Going too hard, too fast can be the death knell because if used in the wrong hands, the messaging is not controlled.' At a glance ASX Code: TTX Share price: $4.35 Shares on issue: 50,331,637 (8.7 million issued in IPO) Market cap: $218 million Chief executive officer: Will Knox (co-founder) Board: Emma Cleary (chair) Ali Fathi (co-founder), Knox, Gillian Shea, David Bottomley, Atlanta Daniel, John Kelly (Atomo), Maurizio Vecchione Financials (half year to December 31, 2024): revenue nil, R&D Tax Incentive $459,000, net loss after tax $2.63 million, cash of $31 million (post IPO) Major identifiable shareholders: Ali Fathi 28%, Radar Ventures (Atlanta Daniel and Rod Drury) 13.3%, David Bottomley and Ryder Capital 11.1%, Will Knox 6.7%. Abrams family 4.95%, Marsden Pty Ltd 4.95%, Aspirate Investments 4.16%
ABC News
an hour ago
- ABC News
Australia battling through severe flu season
Australia's flu season has started hard and fast with a significant surge in influenza cases and hospitalisations. Flu deaths have also risen by almost 40 per cent in the first three months of 2025 compared to the same period last year. The increasing flu numbers come alongside a growing caseload of patients with Respiratory syncytial virus — or RSV. Guest: Dr Michael Wright, President of the Royal Australian College of General Practitioners Dr Michael Wright, President of the Royal Australian College of General Practitioners Producer: Grace Stranger Statement from a Department of Health spokesperson: 'Since launching on 1 April, the RSV mother and infant protection program has helped to protect thousands of newborn babies from RSV in Victoria.''The best protection against severe illness from RSV is through maternal vaccination during pregnancy. However, for babies whose mothers didn't receive the vaccine in time or for infants and young children at higher risk, a new monoclonal antibody nirsevimab has been made available. 'There is no shortage of nirsevimab in Victoria. Providers have been advised to order only what they need for scheduled appointments to ensure fair and efficient distribution. Order limits have been relaxed as the respiratory illness season has progressed.'The Victorian Department of Health has proactively sought to support immunisation providers with additional information and guidance, including direct engagement with GP clinic staff. Victorians can visit the Better Health Channel website for eligibility and access information on the RSV mother and infant protection program.'
ABC News
2 hours ago
- ABC News
Calls for 'wild west' of online sperm donation to be regulated due to 'lifelong consequences'
A leading Australian fertility lawyer is urging governments to regulate the "wild west" of online semen donation, accusing them of being "asleep at the wheel" as women continue to turn to websites and apps to seek donors. Stephen Page is calling on health ministers to look at regulating the space as part of the three-month rapid review of the nation's fertility sector that was sparked by the second Monash IVF mix-up. "There's no regulation, you can set up a website, you can set up an app and bang the drum and get men coming along saying that they will be donors, either by AI (artificial insemination), or NI (natural insemination, or what we used to call sex)," he said. One sperm donation Facebook group, which has more than 21,000 members, asks questions around insemination methods people are comfortable to use, including NI. Last year, ABC's Background Briefing investigated Facebook group sperm exchanges and the "known donor" movement as "wait times and costs see more Australians turn away from traditional sperm banks". The sites are used by some single women and lesbian couples seeking to start a family without the big expense and delays of going to fertility companies, which can involve long wait times to access donor sperm. But Mr Page, who is also on the Fertility Society of Australia and New Zealand (FSANZ) board, cited risks including the lack of a cap on the number of families a donor can donate to through social media and concerns women could be exploited. He said the need for reform was urgent. "It worries me greatly. There's been all this attention about IVF clinics and let's be clear, I think much of that is warranted, but what really worries me is these sites and apps being unregulated," he said. Mr Page said donors should have to provide the site or group's administrator with ID verification, such as a driver's licence or passport. It should then be passed on to a regulatory authority, and if the donor has surpassed the limit on how many families he can create, "remove him from the site", Mr Page said. Donors should also have to declare sexually transmitted infection status, he added. The Brisbane-based lawyer, who made it clear he was not speaking on behalf of FSANZ, believes if social media groups or sites failed to adhere to a proposed code of practice, then they should be shut down. "You can't control people on the phone, you can't control if they meet in the pub or the corner store, but you can certainly control how they communicate through an app or website, which is how most people communicate," he said. "We can't have children waking up in the morning discovering that they've got 57 siblings because there's been a failure of political will to regulate these apps and websites. Asked if any other country regulated this area, he replied: "No, not as far as I'm aware." Adam Hooper, who started Sperm Donation Australia on social media in 2015 because he believed in "known donation", said regulations would "put people in danger". "If regulations are brought in (it) will turn into the dark web where children will never know their donors (sic) identities," Mr Hooper told the ABC in response to a series of questions. "Sperm Donation Australia gives the best advice and goes above and beyond anywhere in the world for a free platform. "Recipients are told to visualise STD tests before commencing." Mr Hooper said regulations did not change human behaviour. "As adults, we all have sexual education," he said. "Their (sic) is people on dating apps right now have (sic) unprotected sex." In response to claims the online semen donation world was the "wild west", he said the "society we live in as a whole is the bigger issue and the real wild west". Mr Hooper said Sperm Donation Australia kicked people out of the group for "lots of reasons", including unreliability, being caught out lying, and having judgemental views on sexuality. "We have a very low tolerance for misbehaviour of any sort," he said. Rebecca Kerner, the chair of the Australia and New Zealand Infertility Counsellors Association (ANZICA), backed Mr Page's call for action. She wrote to Federal Health Minister Mark Butler on behalf of ANZICA several times in 2023, concerned about the lack of regulation and the need for a national donor conception register. ANZICA wrote to Mr Butler again recently, further advocating for reform. Ms Kerner said it was only by establishing a national register that family limits on sperm donors could be monitored and maintained. Without it, she said the risks of psychological distress among donor-conceived children were extreme. "We need to start listening and hearing from people who are conceived in this way," Ms Kerner said. "It is about the potential impact of having large donor sibling groups. For some donor-conceived people, they can certainly feel like they've been cloned. Emily Fae, a Perth-based donor-conceived person and a co-founder of Donor Conceived Australia, said the government has a "duty" to step in. "I absolutely agree that the online donor space is the wild west," she said, adding that donors can lie about themselves, how many children they have fathered, or conceal serious genetic conditions. "Unregulated donation creates lifelong consequences for the donor-conceived people involved. "We deserve accurate medical history, the right to know our genetic relatives, and safeguards against preventable harm." A federal health department spokeswoman said the three-month review agreed to by the nation's health ministers into the assisted reproductive technology (ART) sector would be led by the Victorian government. The spokeswoman said the government was aware of the concerns raised by ANZICA about semen donors advertising online. "Health ministers will consider the outcomes of the review in the coming months, as a matter of priority," she said.
